Signal Diagnostics resolves uninsured-program overpayment allegations for $20.5 million
Oct 11, 2026 edition · GC-2026-0168 · Published 2026-10-11 · Version 4 · Settled
Signal Diagnostics agreed to pay $20.5 million over alleged retention of HRSA Uninsured Program overpayments. DOJ describes duplicate patient profiles, conflicting insurance information and an audit that identified ineligible claims without timely refunds. The settlement resolves allegations without a liability determination.
What happened
DOJ’s September 30 announcement says Signal Diagnostics agreed to pay $20.5 million to resolve False Claims Act allegations concerning HRSA’s COVID-19 Uninsured Program. The program reimbursed eligible providers for services to uninsured people from approximately May 2020 through April 2022. Signal submitted testing and specimen-collection claims from October 2020 through March 2022. The government’s retention allegation covers a different period, January 2022 through May 2023, when Signal allegedly avoided obligations to repay amounts received for patients who had insurance.
According to DOJ, an internal audit begun around January 2022 identified ineligible claims. The alleged errors included duplicate profiles for the same patients with conflicting insurance information and claims submitted despite alternative coverage being on file. The government contends that Signal continued auditing and calculating the overpayment while knowingly and improperly avoiding repayment through May 2023. That sequence makes the connection between eligibility review, quantification and refund decisions central to the case, rather than treating the audit itself as the completed remedy. The settlement resolves allegations only, with no determination of liability; it does not reopen the closed reimbursement program or establish that settlement funds were already collected.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
An internal eligibility audit needs a controlled path from identified ineligible claims to quantified amounts and repayment decisions. This closed-program case does not reopen HRSA reimbursement.
Recommended action
Revenue Cycle and Compliance should reconcile duplicate identities and insurance information, preserve the audit trail and review identified legacy overpayments with Finance and counsel.
Case details
- agencies
- U.S. Department of Justice
- entities
- Signal Diagnostics LLC
- action Type
- Settlement
- event Date
- 2026-09-30
- alleged Conduct
- Alleged failure to refund uninsured-program payments for insured patients.
- resolution
- Civil settlement resolving allegations; no adjudication of liability is asserted.
Operational lessons
- Validate historical uninsured-program eligibility matching, later-discovered insurance, refund decisions and escalation documentation.
Sources
- Signal Diagnostics agrees to pay over $20 million to settle FCA allegationsOfficial · DOJ · 2026-09-30 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →